• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Surrozen Inc.

    5/15/25 4:30:10 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SRZN alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Surrozen, Inc.

    (Name of Issuer)


    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)


    86889P208

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    86889P208


    1Names of Reporting Persons

    Perceptive Advisors LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    166,666.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    166,666.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    166,666.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.9 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    CUSIP No.
    86889P208


    1Names of Reporting Persons

    Joseph Edelman
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    166,666.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    166,666.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    166,666.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.9 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    86889P208


    1Names of Reporting Persons

    Perceptive Life Sciences Master Fund, Ltd.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    166,666.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    166,666.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    166,666.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.9 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Surrozen, Inc.
    (b)Address of issuer's principal executive offices:

    171 Oyster Point Blvd, Suite 400, South San Francisco, CA 94080
    Item 2. 
    (a)Name of person filing:

    The names of the persons filing this report (collectively, the "Reporting Persons") with respect to shares of Common Stock, par value $0.0001 per share (the "Common Stock") of Surrozen, Inc. (the "Issuer") are: (i) Perceptive Advisors LLC ("Perceptive Advisors") (ii) Joseph Edelman ("Mr. Edelman") (iii) Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund")
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of each of the Reporting Persons is: 51 Astor Place, 10th Floor, New York, NY 10003
    (c)Citizenship:

    Perceptive Advisors is a Delaware limited liability company. Mr. Edelman is a United States citizen. The Master Fund is a Cayman Islands corporation.
    (d)Title of class of securities:

    Common Stock, $0.0001 par value per share
    (e)CUSIP No.:

    86889P208
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 of the cover pages to this Schedule 13G. The amounts reported herein assume the exercise of warrants held by the Reporting Persons to purchase 166,666 shares of Common Stock (the "Warrants"). The ownership percentages reported are based on 8,494,584 shares of Common Stock outstanding as of March 31, 2025, as reported in the Issuer's Prospectus filed pursuant to Rule 424(b)(5) with the Securities and Exchange Commission on May 1, 2025, and assume the exercise of the Warrants for 166,666 shares of Common Stock. The Master Fund holds Warrants exercisable for 166,666 shares of Common Stock. Perceptive Advisors serves as the investment manager to the Master Fund and may be deemed to beneficially own such shares of Common Stock. Mr. Edelman is the managing member of Perceptive Advisors and may be deemed to beneficially own such shares of Common Stock.
    (b)Percent of class:

    Perceptive Advisors: 1.9% Mr. Edelman: 1.9% Master Fund: 1.9
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Perceptive Advisors: 0 Mr. Edelman: 0 Master Fund: 0

     (ii) Shared power to vote or to direct the vote:

    Perceptive Advisors: 166,666 Mr. Edelman: 166,666 Master Fund: 166,666

     (iii) Sole power to dispose or to direct the disposition of:

    Perceptive Advisors: 0 Mr. Edelman: 0 Master Fund: 0

     (iv) Shared power to dispose or to direct the disposition of:

    Perceptive Advisors: 166,666 Mr. Edelman: 166,666 Master Fund: 166,666

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Perceptive Advisors LLC
     
    Signature:/s/ Joseph Edelman
    Name/Title:Joseph Edelman, Managing Member
    Date:05/15/2025
     
    Joseph Edelman
     
    Signature:/s/ Joseph Edelman
    Name/Title:Joseph Edelman
    Date:05/15/2025
     
    Perceptive Life Sciences Master Fund, Ltd.
     
    Signature:/s/ Joseph Edelman
    Name/Title:Joseph Edelman, Managing Member
    Date:05/15/2025
    Get the next $SRZN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SRZN

    DatePrice TargetRatingAnalyst
    1/30/2025$32.00Buy
    H.C. Wainwright
    1/3/2025$45.00Neutral → Buy
    Guggenheim
    10/11/2021$11.00Buy
    B of A Securities
    9/15/2021$20.00Buy
    Guggenheim
    9/7/2021$19.00Buy
    Stifel
    More analyst ratings

    $SRZN
    SEC Filings

    See more
    • SEC Form EFFECT filed by Surrozen Inc.

      EFFECT - Surrozen, Inc./DE (0001824893) (Filer)

      5/27/25 12:15:19 AM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-3 filed by Surrozen Inc.

      S-3 - Surrozen, Inc./DE (0001824893) (Filer)

      5/20/25 4:30:56 PM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Surrozen Inc.

      SCHEDULE 13G/A - Surrozen, Inc./DE (0001824893) (Subject)

      5/15/25 4:55:17 PM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SRZN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway

      Newly granted patent is part of the expanding intellectual property portfolio directed to: -generating novel and selective Wnt surrogate molecules with potentially broad therapeutic utility and -incorporating novel discoveries related to requirements for efficient and selective Wnt pathway signaling SOUTH SAN FRANCISCO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt Pathway for tissue repair and regeneration, today announced the issuance of U.S. Patent No. 12,297,278. Surrozen has six issued U.S. patents, 10 patents issued in other countries, 11 patent fami

      5/14/25 8:30:01 AM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update

      SOUTH SAN FRANCISCO, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, with a focus on severe eye diseases, today announced financial results for the first quarter ended March 31, 2025, and provided a business update. Business Highlights Surrozen has pivoted its focus to its ophthalmology pipeline, leveraging its Wnt biology expertise and antibody technologies to develop novel treatments for severe eye diseases, including age-related macular degeneration (AMD) and diabetic retinopathy. The Company discont

      5/9/25 4:05:08 PM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates

      SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, with a focus on severe eye diseases, today provided fourth quarter and full year 2024 financial results and business updates. Research and Development Pipeline Highlights The company prioritized its ophthalmology pipeline programs that have the potential to provide new or improved treatment options in multiple severe and disabling eye diseases. Surrozen will focus its Wnt biology expertise and Wnt signal modulation antibody technologies on its oph

      3/31/25 4:05:16 PM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SRZN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Surrozen with a new price target

      H.C. Wainwright initiated coverage of Surrozen with a rating of Buy and set a new price target of $32.00

      1/30/25 7:17:42 AM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Surrozen upgraded by Guggenheim with a new price target

      Guggenheim upgraded Surrozen from Neutral to Buy and set a new price target of $45.00

      1/3/25 7:50:23 AM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • B of A Securities initiated coverage on Surrozen with a new price target

      B of A Securities initiated coverage of Surrozen with a rating of Buy and set a new price target of $11.00

      10/11/21 7:02:26 AM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SRZN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Exec. Vice President, Research Li Yang was granted 400 shares, increasing direct ownership by 3% to 13,043 units (SEC Form 4)

      4 - Surrozen, Inc./DE (0001824893) (Issuer)

      6/16/25 6:58:51 PM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CFO and COO Williams Charles O was granted 400 shares, increasing direct ownership by 4% to 9,382 units (SEC Form 4)

      4 - Surrozen, Inc./DE (0001824893) (Issuer)

      6/16/25 6:47:48 PM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Parker Craig C was granted 400 shares, increasing direct ownership by 6% to 7,024 units (SEC Form 4)

      4 - Surrozen, Inc./DE (0001824893) (Issuer)

      6/16/25 6:44:45 PM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SRZN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Column Group Iii Gp, Lp bought $11,999,991 worth of shares (1,034,482 units at $11.60) (SEC Form 4)

      4 - Surrozen, Inc./DE (0001824893) (Issuer)

      3/28/25 8:57:08 PM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Column Group Iii Gp, Lp bought $2,999,994 worth of shares (193,548 units at $15.50) (SEC Form 4) (Amendment)

      4/A - Surrozen, Inc./DE (0001824893) (Issuer)

      4/17/24 4:14:56 PM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kutzkey Tim bought $2,999,994 worth of shares (193,548 units at $15.50) (SEC Form 4) (Amendment)

      4/A - Surrozen, Inc./DE (0001824893) (Issuer)

      4/17/24 4:10:51 PM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SRZN
    Leadership Updates

    Live Leadership Updates

    See more
    • Surrozen Strengthens Board of Directors with the Appointment of Eric Bjerkholt

      SOUTH SAN FRANCISCO, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced that Eric Bjerkholt has been appointed to the Board of Directors. Surrozen's Board of Directors now includes nine members with extensive experience across diverse disciplines in biotechnology and pharmaceutical development. Mr. Bjerkholt brings extensive business leadership experience across a broad range of roles and is currently CFO of Chinook Therapeutics. He most recently served as CFO of Aimmune Therapeutics, Inc. overseeing t

      4/5/23 8:30:00 AM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Surrozen Announces Appointment of Liz Nguyen as Vice President and Head of Human Resources

      SOUTH SAN FRANCISCO, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc. (NASDAQ:SRZN), a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, today announced that Elizabeth "Liz" Nguyen has been appointed as Vice President and Head of Human Resources (HR). Ms. Nguyen brings over 20 years of experience in organizational design, talent recruitment, building a performance culture, planning and leadership development. "Liz is joining Surrozen at a time of tremendous growth as we advance our two lead programs into the clinic and continue our momentum and progress on our broad research pipeline," said Craig Parker, President and Chief

      9/23/21 8:30:00 AM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SRZN
    Financials

    Live finance-specific insights

    See more
    • Surrozen Provides Fourth Quarter and Full Year 2022 Financial Results and Update on Clinical Pipeline and Corporate Progress

      Enrolled first patient in SZN-043 Ph 1a clinical trial in chronic liver disease with data expected by the end of 2023 Expect to begin SZN-043 Ph1b clinical trial in severe alcoholic hepatitis in 2024 with proof-of-concept data expected in the second half of 2024 Expect to reinitiate SZN-1326 Ph1a clinical trial in healthy volunteers by mid-2023 with data expected by the end of 2023 Anticipate potential proof-of-concept data for SZN-1326 in ulcerative colitis in the second half of 2024 Expect to nominate a fourth product candidate by the end of 2023 Corporate prioritization and restructuring result in cash runway into the second half of 2024 SOUTH SAN FRANCISCO, Calif., March 22, 2023

      3/22/23 4:01:00 PM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Surrozen To Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 22, 2023

      SOUTH SAN FRANCISCO, Calif., March 20, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), today announced that it will report fourth quarter and full year 2022 financial results and provide a corporate and pipeline progress report on Wednesday, March 22, 2023 after the close of the U.S. financial markets.   Company management will host a live audio webcast at 4:30 PM Eastern Time to discuss the corporate update and pipeline progress. Interested parties may join the audio webcast via the Investor website at www.surrozen.com. To ensure a timely connection, it is recommended that individuals register at least 15 minutes prior to the start of the webcast. Ab

      3/20/23 4:30:00 PM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SRZN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Surrozen Inc.

      SC 13G/A - Surrozen, Inc./DE (0001824893) (Subject)

      11/14/24 4:34:39 PM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Surrozen Inc.

      SC 13G/A - Surrozen, Inc./DE (0001824893) (Subject)

      11/13/24 5:42:02 PM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Surrozen Inc.

      SC 13G/A - Surrozen, Inc./DE (0001824893) (Subject)

      11/8/24 11:26:54 AM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care